The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome (SAAVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01432106
Recruitment Status : Withdrawn (Novartis terminated all projects involving aliskiren. Findings of the DMC overseeing the ALTITUDE clinical trial found a higher incidence of adverse events.)
First Posted : September 12, 2011
Last Update Posted : November 18, 2013
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Kenneth A. Jamerson, University of Michigan

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Actual Primary Completion Date : December 2012
  Actual Study Completion Date : December 2012